4 / 12
Page 40
conferenceseries
.com
Volume 8
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Euro Dementia 2018
May 24-25, 2018
May 24-25, 2018 | Vienna, Austria
11
th
International Conference on
Alzheimers Disease & Dementia
The importance of platform in public-private partnerships and social care for Alzheimer’s disease
Manabu Tamura, Sayaka Tomihara, Shinichiro Okazaki, Hiroki Yokote, Masahiro Uemura
and
Kazumi Nishikawa
Ministry of Economy, Trade and Industry, Japan
I
n patients with Alzheimer’s disease (AD) who do not have surgical indications, anti-AD therapy is usually administered,
while there are only four more or less effective drugs available. Of note, currently no medication exists, which can cure AD
and all therapeutics may only slow the disease progression. Considering that, as expected, the number of AD patients will
increase, gradually making it more difficult for doctors to manage all cases of dementia, which will require modification of the
healthcare system in general. It is particularly important in Japan, with a now rapidly aging society; the government should
clearly recognize possible increase in the incidence of dementia. Currently, there are a variety of neuroimaging initiatives for
AD worldwide (ADNI, CATI, etc.), and several clinical trials have been initiated (EPAD consortium, A4, GAP foundation,
Memento, etc.). Japan thus needs international collaboration with medical practitioners and scientists from other countries. On
the other hand, it is important to create AD platform in a way of new and innovative public-private partnership (PPP). This AD
platform should aim at dementia research as the main target (e.g., risk reduction, prevention, early diagnosis, treatment, and
life support), and also to establish common paradigm directed at development of the registry, investigated patients cohort, and
biobank. Collaboration of private enterprises, academia and public entities (e.g., basic science in MEXT, clinical application
in MLHW, integration of different fields in METI) may have an immediate impact on the development of dementia research.
In addition, Japan may further accelerate AD studies at a new system for medical research and development (Japan Agency
for Medical Research and Development–AMED), which has extended its activities and currently grips project and budget
management (e.g., new orange plan in MLHW). There are no doubts that fair evaluation of clinical results in AD considering
COI (conflict of interests) should be done. In addition, it is important to make this information available to public in an easy-
to-understand and accurate manner. Practical analysis of social environmental factors leading to AD, appropriate preventive
measures, and treatment results are required in the future, since currently there is no therapeutic agent for AD with clearly
confirmed clinical efficacy.
Figure 1. Scheme for PPP dementia platform.
Recent Publications
1. Saito T, TamuraM, ChernovMF, Ikuta S, Muragaki Y, et al. (2018) Neurophysiological monitoring and awake craniotomy
for resection of intracranial gliomas. Progress in Neurological Surgery 30:117–158.
2. Aonuma S, Gomez-Tames J, Laakso I, Takakura T, Tamura M, et al. (2018) A high-resolution computational localization
method for transcranial magnetic stimulation mapping. Neuroimage 172:85–93.
Manabu Tamura et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI:10.4172/2161-0460-C3-042